Cisplatin and gemcitabine in the management of metastatic penile cancer.
Penile cancer is rare and receives little public attention. There are few treatment options for advanced disease. The most active regimen to date is a combination of bleomycin, methotrexate, and cisplatin. However the treatment-related mortality is 11% and hence this combination has not been adapted as a standard of care. We report two cases of advanced penile cancer where a sustained palliative response was observed with combination chemotherapy using cisplatin and gemcitabine. Our experience demonstrates that this is a well tolerated regimen active in this setting.
Power
Derek G
DG
Department of Medical Oncology, St. James's Hospital, Dublin, Ireland. drdgpower@gmail.com
Galvin
David J
DJ
Cuffe
Sinead
S
McVey
Gerald P
GP
Mulholland
Paul J
PJ
Farrelly
Cormac
C
Delaney
David W
DW
O'Byrne
Kenneth J
KJ
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010412:Penile Neoplasms / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome; D000093542:Gemcitabine
D003841:Deoxycytidine; D001761:Bleomycin; D002945:Cisplatin; D008727:Methotrexate; D000093542:Gemcitabine